false
0001624326
0001624326
2026-06-24
2026-06-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 24, 2026
PAVMED
INC.
(Exact
Name of Registrant as Specified in Charter)
| Delaware |
|
001-37685 |
|
47-1214177 |
| (State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
| of Incorporation) |
|
File Number) |
|
Identification No.) |
| 360
Madison Avenue, 25th Floor, New
York, New
York |
|
10017 |
| (Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (917) 813-1828
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
| Title of
each class |
|
Trading symbol(s) |
|
Name of each
exchange on which registered |
| Common Stock, Par Value $0.01 Per Share |
|
PAVM |
|
The Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. |
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. |
The
information disclosed under Item 5.07 is incorporated herein by reference.
| Item 5.07. |
Submission of Matters to a Vote
of Security Holders. |
On
June 24, 2026, PAVmed Inc. (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”).
Stockholders representing approximately 59.6% of the shares outstanding and entitled to vote were present in person or by proxy. At the
Annual Meeting, the stockholders elected each of management’s nominees for director and approved the other matters considered.
A description of the matters considered by the stockholders and a tally of the votes on each such matter are set forth below.
1.
The election of two members of the Company’s board of directors (the “Board”) as Class A directors, to hold
office until the third succeeding annual meeting and until their respective successors are duly elected and qualified. The Board is divided
into three classes, Class A, Class B and Class C. As of the Annual Meeting, there were two directors in Class A, Ronald M. Sparks and
Timothy Baxter, whose terms expired at the Annual Meeting, two directors in Class B, Sundeep Agrawal, M.D. and Debra J. White, whose
terms expire at the 2027 annual meeting of stockholders, and two directors in Class C, Lishan Aklog, M.D. and Michael J. Glennon, whose
terms expire at the 2028 annual meeting of stockholders. The board nominated Mr. Sparks and Mr. Baxter for re-election as Class A directors.
Each of the board’s nominees for director was elected, as follows:
| Name | |
For | | |
Authority Withheld | | |
Broker Non-Votes | |
| Ronald M. Sparks | |
| 3,810,460 | | |
| 67,490 | | |
| 457,041 | |
| Timothy Baxter | |
| 3,815,060 | | |
| 62,890 | | |
| 457,041 | |
2.
A proposal to approve amendments to the Company’s Employee Stock Purchase Plan (the “ESPP”) to (i) increase
the total number of shares of the Company’s common stock available under the ESPP by an additional 200,000 shares, from 15,774
shares to 215,774 shares and (ii) raise the annual limit for increases under the evergreen provision from 5,556 to 500,000 shares. The
amendments were approved, as follows:
| For | |
Against | | |
Abstain | | |
Broker Non-Votes | |
| 3,780,854 | |
| 95,874 | | |
| 1,222 | | |
| 457,041 | |
A
more complete description of the ESPP, as amended, is set forth beginning on page 8 under “The ESPP Proposal” in the
Definitive Proxy Statement on Schedule 14A, filed by the Company on April 30, 2026 (the “Definitive Proxy Statement”),
which description is incorporated herein by reference. The description of the amendments does not purport to be complete and is qualified
in its entirety by reference to the full text of the ESPP, which is included as Annex A to the Definitive Proxy Statement and is incorporated
herein by reference.
3.
A proposal to ratify the appointment of CBIZ CPAs P.C. as the Company’s independent registered certified public accounting firm
for the year ending December 31, 2026. The ratification of the appointment of CBIZ CPAs P.C. was approved, as follows:
| For | |
Against | | |
Abstain | | |
Broker Non-Votes | |
| 4,306,623 | |
| 25,814 | | |
| 2,554 | | |
| — | |
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits:
| Exhibit No. |
|
Description |
| |
|
|
| 10.1 |
|
Employee Stock Purchase Plan, as amended and restated on June 24, 2026 (incorporated by reference to Annex A to the Definitive Proxy Statement). |
| |
|
|
| 104 |
|
Cover Page Interactive
Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Dated: June 24, 2026 |
PAVMED INC. |
| |
|
|
| |
By: |
/s/ Dennis McGrath |
| |
|
Dennis McGrath |
| |
|
President and Chief Financial Officer |